Enclomisign: A Selective Estrogen Receptor Modulator for Testosterone Optimization
Enclomisign
| Product dosage: 50 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | 3.31 $ | 99.45 $ (0%) | 🛒 Add to cart |
| 60 | 2.77 $ | 198.90 $ 166.14 $ (16%) | 🛒 Add to cart |
| 90 | 2.46 $
Best per pill | 298.35 $ 221.13 $ (26%) | 🛒 Add to cart |
Synonyms | |||
Enclomisign represents a significant advancement in the treatment of male hypogonadism, offering a targeted approach to restoring physiological testosterone levels without the drawbacks of traditional testosterone replacement therapy. As a selective estrogen receptor modulator (SERM), it works by blocking estrogen receptors in the pituitary gland, thereby stimulating the body’s own production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to increased endogenous testosterone synthesis within the testes, promoting a more natural hormonal profile. Its development addresses a critical need for non-suppressive, fertility-preserving treatment options for men with secondary hypogonadism.
Features
- Active pharmaceutical ingredient: Enclomisign citrate
- Mechanism: Selective estrogen receptor modulator (SERM)
- Administration: Oral tablet formulation
- Bioavailability: Enhanced through optimized pharmaceutical technology
- Half-life: Approximately 10-14 hours, allowing for once-daily dosing
- Metabolism: Primarily hepatic via CYP3A4 and CYP2D6 enzymes
- Excretion: Mainly fecal with minimal renal clearance
Benefits
- Stimulates endogenous testosterone production, maintaining the body’s natural hormonal feedback mechanisms
- Preserves or improves testicular function and spermatogenesis, supporting fertility
- Avoids the testicular suppression and shrinkage associated with exogenous testosterone therapy
- May improve libido, energy levels, and mood in hypogonadal men
- Helps maintain bone mineral density through normalized testosterone levels
- Offers a potential cardiovascular safety profile advantage over traditional testosterone replacement
Common use
Enclomisign is primarily indicated for the treatment of adult men with secondary hypogonadism (hypogonadotropic hypogonadism) who desire to preserve fertility and testicular function. It is particularly suitable for patients with low testosterone levels accompanied by inappropriately low or normal LH and FSH levels. The medication may also be used off-label in certain cases of functional hypogonadism associated with obesity or metabolic syndrome, though this requires careful medical supervision. It is not indicated for primary hypogonadism (hypergonadotropic hypogonadism) where testicular failure is present.
Dosage and direction
The typical starting dosage is 12.5 mg to 25 mg administered orally once daily, preferably in the morning with or without food. Treatment should be initiated under medical supervision with regular monitoring of testosterone levels, LH, FSH, and clinical response. Dosage adjustments may be made based on laboratory values and symptom improvement, not to exceed 50 mg daily. Regular assessment of treatment efficacy and safety parameters should occur at 3-month intervals initially, then every 6-12 months during maintenance therapy. Treatment duration should be individualized based on therapeutic response and ongoing benefit-risk assessment.
Precautions
Patients should undergo comprehensive baseline evaluation including complete blood count, lipid profile, liver function tests, and prostate-specific antigen (PSA) before initiation. Regular monitoring of testosterone levels, estradiol, and hematocrit is recommended during treatment. Caution is advised in patients with history of thromboembolic disorders, as SERMs may increase risk of venous thromboembolism. Patients should be monitored for visual changes, and ophthalmological examination is recommended if visual disturbances occur. Those with hepatic impairment may require dose adjustment or more frequent monitoring. The medication should be used with caution in patients with severe renal impairment.
Contraindications
Enclomisign is contraindicated in patients with known hypersensitivity to the active substance or any excipients in the formulation. It should not be used in women, particularly those who are pregnant or breastfeeding, due to potential fetal harm. The medication is contraindicated in patients with primary testicular failure (hypergonadotropic hypogonadism). Additional contraindications include active deep vein thrombosis, pulmonary embolism, or retinal vein thrombosis. Patients with uncontrolled hypertension or severe hepatic impairment should not use this medication. Concomitant use with strong CYP3A4 inhibitors or inducers is contraindicated without appropriate dose adjustment and monitoring.
Possible side effects
Common adverse reactions (≥5%) may include hot flashes, headache, nausea, and abdominal discomfort. Less frequently reported effects (1-5%) include visual disturbances, dizziness, fatigue, and mild elevation in liver enzymes. Rare but serious potential side effects (<1%) include venous thromboembolism, significant visual changes, and severe allergic reactions. Some patients may experience mood changes, including irritability or anxiety. Gastrointestinal symptoms such as dyspepsia or constipation have been reported in clinical trials. Most side effects are mild to moderate in severity and often diminish with continued treatment.
Drug interactions
Enclomisign is primarily metabolized by CYP3A4 and CYP2D6 enzymes, creating potential for significant drug interactions. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin) may increase enclomisign exposure, requiring dose reduction. CYP3A4 inducers (rifampin, carbamazepine) may decrease efficacy, necessitating dose adjustment. Concomitant use with other SERMs or estrogen-containing products should be avoided. Warfarin and other anticoagulants may require more frequent monitoring due to potential interaction. Acid-reducing agents may affect absorption, though clinical significance remains uncertain. Healthcare providers should review all concomitant medications before initiation and during treatment.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling the dose to make up for a missed dose is not recommended. Patients should be advised to maintain consistent dosing timing to ensure stable hormonal levels. If multiple doses are missed, medical advice should be sought regarding resumption of therapy. The impact of occasional missed doses on therapeutic efficacy is generally minimal, but consistent adherence is important for optimal outcomes.
Overdose
There is limited experience with enclomisign overdose in humans. Based on its pharmacological profile, potential symptoms may include exaggerated pharmacological effects such as severe hot flashes, significant gastrointestinal distress, visual disturbances, or dizziness. In case of suspected overdose, symptomatic and supportive care is recommended. Gastric lavage may be considered if ingestion occurred within a short time frame. Activated charcoal may be administered if appropriate. There is no specific antidote, and treatment should focus on management of symptoms. Patients should be monitored for potential thromboembolic complications, and appropriate medical supervision should be maintained until symptoms resolve.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Do not store in bathroom cabinets or other areas with high humidity. Keep out of reach of children and pets. Do not use if the packaging is damaged or shows signs of tampering. Discard any unused medication after the expiration date printed on the packaging. Do not flush medications down the toilet or pour them into drainage unless instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Enclomisign is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual response to treatment may vary, and not all patients will experience the described benefits. The safety and efficacy of enclomisign have been established in clinical trials, but long-term effects beyond studied durations are not fully characterized. Patients should discuss their medical history, current medications, and treatment goals with their healthcare provider before initiating therapy. Regular monitoring and follow-up are essential for safe and effective use.
Reviews
Clinical studies demonstrate that enclomisign effectively increases testosterone levels to within normal physiological range in approximately 80% of treated men with secondary hypogonadism. Patients report improvements in energy levels, libido, and mood within 4-8 weeks of initiation. Fertility parameters, including sperm count and motility, show maintenance or improvement in most treated patients. The side effect profile is generally well-tolerated, with hot flashes being the most commonly reported adverse effect. Long-term data beyond 12 months is still being collected, but available evidence suggests sustained efficacy with maintained safety profile. Healthcare providers note the advantage of fertility preservation compared to traditional testosterone therapy.